person · Reporting owner

Munshi Amit

Disclosed activity across 7 companies

Tapewire entity: 34471
SEC CIK: 0001612551

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Arcutis Biotherapeutics, Inc.ARQT · Entity 4236	Director	June 05, 2026	June 10, 2026
Damora Therapeutics, Inc.GLTO · Entity 4602	Director	June 18, 2025	June 20, 2025
Inhibikase Therapeutics, Inc.IKT · Entity 5838	Director	June 26, 2026	June 30, 2026
Pulmatrix, Inc.PULM · Entity 8249	Director	January 28, 2021	February 02, 2021
Social Capital Suvretta Holdings Corp. IVDNAD · Entity 123913	Director	June 29, 2021	June 29, 2021
Zura Bio LtdZURA · Entity 5413	Director	June 17, 2026	June 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcutis Biotherapeutics, Inc.

Report date June 05, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	9,799	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 5,778 · Balance 9,799 F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.23 · Expires 2036-06-05	Direct	16,667	Reported balance After 2026-06-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-05 · Grant · Acquired 16,667 · Balance 16,667 F2: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

F2: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Damora Therapeutics, Inc.

Report date June 18, 2025 · Filed June 20, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2035-06-18	Direct	720	Reported balance After 2025-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-18 · Grant · Acquired 720 · Balance 720 F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Inhibikase Therapeutics, Inc.

Report date June 26, 2026 · Filed June 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2036-06-26	Direct	155,000	Reported balance After 2026-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-26 · Grant · Acquired 155,000 · Balance 155,000 F1: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Pulmatrix, Inc.

Report date January 28, 2021 · Filed February 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2031-01-28	Direct	15,000	Reported balance After 2021-01-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-01-28 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.

Social Capital Suvretta Holdings Corp. IV

Report date June 29, 2021 · Filed June 29, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2021-06-29 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

Zura Bio Ltd

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2036-06-17	Direct	51,000	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 51,000 · Balance 51,000 F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARENA PHARMACEUTICALS INC

Report date March 11, 2022 · Filed March 11, 2022

Section 16 reporting ended · disclosed 2022-03-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2022-03-11 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2022-03-08 · Gift · Disposed 10,500 · Balance 114,897 F1: The reporting person gifted the shares to a 501(c)(3) public charity. Row 2 · 2022-03-11 · Other · Disposed 250 · Balance 114,647 F2: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Row 3 · 2022-03-11 · Other · Disposed 28,800 · Balance 85,847 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. Row 4 · 2022-03-11 · Other · Disposed 85,847 · Balance 0 F4: Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a "2022 Issuer RSU") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement).
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.50	Direct	Reported balance After 2022-03-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-03-11 · Disposition to issuer · Disposed 138,139 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.60	Direct	Reported balance After 2022-03-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-03-11 · Disposition to issuer · Disposed 56,861 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.60	Direct	Reported balance After 2022-03-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-03-11 · Disposition to issuer · Disposed 310,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.94	Direct	Reported balance After 2022-03-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-03-11 · Disposition to issuer · Disposed 285,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.60	Direct	Reported balance After 2022-03-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-03-11 · Disposition to issuer · Disposed 270,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $80.08	Direct	Reported balance After 2022-03-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-03-11 · Disposition to issuer · Disposed 168,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Employee Performance Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-03-11 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-03-11 · Disposition to issuer · Disposed 42,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person gifted the shares to a 501(c)(3) public charity.

F2: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes.

F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes.

F4: Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a "2022 Issuer RSU") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement).

F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.

F6: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 26, 2026 Filed Jun 30, 2026 20:05 UTC	Inhibikase Therapeutics, Inc. IKT · Entity 5838	GrantStock Option (Right to Buy) · Derivative	155,000	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001193125-26-290470 · ownership.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2036-06-26 F1 · derivative.exercise_date: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. Read SEC document
June 17, 2026 Filed Jun 22, 2026 20:15 UTC	Zura Bio Ltd ZURA · Entity 5413	GrantShare Option (Right to Buy) · Derivative	51,000	$0.00 Strike: $3.62	$0.00	Disclosure SEC source: 0001612551-26-000002 · form4-06222026_040605.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Class A Ordinary Shares · 51,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document
June 05, 2026 Filed Jun 10, 2026 01:21 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (right to buy) · Derivative	16,667	$0.00 Strike: $21.23	$0.00	Disclosure SEC source: 0001628280-26-042041 · wk-form4_1781054459.xml · derivative · entry 2 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2036-06-05 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document
June 05, 2026 Filed Jun 10, 2026 01:21 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantCommon Stock	5,778	$0.00	$0.00	Disclosure SEC source: 0001628280-26-042041 · wk-form4_1781054459.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,799 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document
February 21, 2026 Filed Feb 25, 2026 01:48 UTC	Inhibikase Therapeutics, Inc. IKT · Entity 5838	Disposition to issuerCommon Stock	19,089	$0.00	$0.00	Disclosure SEC source: 0001193125-26-068063 · ownership.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,176 F1 · shares: As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture. F1 · balance_after: As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture. Read SEC document
December 04, 2025 Filed Dec 9, 2025 01:02 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (right to buy) · Derivative	6,177	$0.00 Strike: $31.16	$0.00	Disclosure SEC source: 0001628280-25-055927 · wk-form4_1765242175.xml · derivative · entry 3 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,177 Underlying: Common Stock · 6,177 shares Expires 2035-12-04 F3 · shares: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date. F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date. Read SEC document
December 04, 2025 Filed Dec 9, 2025 01:02 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (right to buy) · Derivative	16,502	$0.00 Strike: $31.16	$0.00	Disclosure SEC source: 0001628280-25-055927 · wk-form4_1765242175.xml · derivative · entry 2 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,502 Underlying: Common Stock · 16,502 shares Expires 2035-12-04 F2 · shares: 1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of December 4, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date. F2 · derivative.exercise_date: 1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of December 4, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date. Read SEC document
December 04, 2025 Filed Dec 9, 2025 01:02 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantCommon Stock	2,021	$0.00	$0.00	Disclosure SEC source: 0001628280-25-055927 · wk-form4_1765242175.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,021 F1 · security: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date. F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date. Read SEC document
June 30, 2025 Filed Jul 2, 2025 23:43 UTC	Inhibikase Therapeutics, Inc. IKT · Entity 5838	GrantStock Option (Right to Buy) · Derivative	108,176	$0.00 Strike: $1.95	$0.00	Disclosure SEC source: 0000950170-25-093432 · ownership.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,176 Underlying: Common Stock · 108,176 shares Expires 2032-06-30 F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. Read SEC document
June 18, 2025 Filed Jun 20, 2025 11:00 UTC	Damora Therapeutics, Inc. GLTO · Entity 4602	GrantStock Option (right to buy) · Derivative	720	$0.00 Strike: $3.22	$0.00	Disclosure SEC source: 0000950170-25-088166 · ownership.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720 Underlying: Common Stock · 720 shares Expires 2035-06-18 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document
May 21, 2025 Filed May 22, 2025 21:37 UTC	Zura Bio Ltd ZURA · Entity 5413	GrantShare Option (Right to Buy) · Derivative	51,000	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001415889-25-014223 · form4-05222025_090505.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Class A Ordinary Shares · 51,000 shares Expires 2035-05-21 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document
February 21, 2025 Filed Aug 28, 2025 23:48 UTC	Inhibikase Therapeutics, Inc. IKT · Entity 5838	GrantCommon Stock	57,265	$0.00	$0.00	Disclosure SEC source: 0001193125-25-191463 · ownership.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,265 F1 · shares: Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. ("CorHepta") on February 21, 2025 (the "Closing Date") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 9,544 shares vested on the Closing Date, 28,632 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 19,089 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 19,089 shares shall be forfeited. Read SEC document
February 14, 2025 Filed Feb 20, 2025 01:11 UTC	Inhibikase Therapeutics, Inc. IKT · Entity 5838	GrantStock Option (Right to Buy) · Derivative	116,585	$0.00 Strike: $2.35	$0.00	Disclosure SEC source: 0000950170-25-023586 · ownership.xml · derivative · entry 2 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,585 Underlying: Common Stock · 116,585 shares Expires 2035-02-14 F2 · derivative.exercise_date: The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026. Read SEC document
February 14, 2025 Filed Feb 20, 2025 01:11 UTC	Inhibikase Therapeutics, Inc. IKT · Entity 5838	GrantStock Option (Right to Buy) · Derivative	56,600	$0.00 Strike: $2.35	$0.00	Disclosure SEC source: 0000950170-25-023586 · ownership.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,600 Underlying: Common Stock · 56,600 shares Expires 2035-02-14 F1 · derivative.exercise_date: The options vested and became exercisable on February 14, 2025. Read SEC document
December 09, 2024 Filed Dec 11, 2024 21:45 UTC	Zura Bio Ltd ZURA · Entity 5413	GrantShare Option (Right to Buy) · Derivative	117,000	$0.00 Strike: $2.76	$0.00	Disclosure SEC source: 0001415889-24-028974 · form4-12112024_041207.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Class A Ordinary Shares · 117,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from October 23, 2024; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document
October 21, 2024 Filed Oct 23, 2024 23:43 UTC	Inhibikase Therapeutics, Inc. IKT · Entity 5838	GrantStock Option (right to buy) · Derivative	60,000	$0.00 Strike: $2.22	$0.00	Disclosure SEC source: 0000950170-24-116780 · ownership.xml · derivative · entry 2 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-10-21 F1 · derivative.exercise_date: The option shares vest 50% on each of the first two anniversaries of October 21, 2024. Read SEC document
October 21, 2024 Filed Oct 23, 2024 23:43 UTC	Inhibikase Therapeutics, Inc. IKT · Entity 5838	PurchaseCommon Stock	365,000	$1.37	$500,050.00	Disclosure SEC source: 0000950170-24-116780 · ownership.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Amit Munshi Revocable Trust Disclosed balance after: 365,000 Read SEC document
June 20, 2024 Filed Jun 21, 2024 20:00 UTC	Damora Therapeutics, Inc. GLTO · Entity 4602	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $0.49	$0.00	Disclosure SEC source: 0000950170-24-076188 · ownership.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 20, 2024, the date of the Issuer's 2024 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document
April 22, 2024 Filed Apr 24, 2024 22:52 UTC	Zura Bio Ltd ZURA · Entity 5413	PurchaseClass A ordinary shares	159,744	$3.13	$499,998.72	Disclosure SEC source: 0001415889-24-011480 · form4-04242024_100408.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 777,384 F1 · kind: These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and the Reporting Person at a purchase price of $3.13 per share. Read SEC document
April 22, 2024 Filed Sep 6, 2024 21:32 UTC Amendment	Zura Bio Ltd ZURA · Entity 5413	GrantClass A ordinary shares	159,744	$3.13	$499,998.72	Disclosure SEC source: 0001415889-24-023028 · form4a-09062024_090909.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 777,384 F1 · kind: On April 24, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'A' instead of transaction code 'P'. F2 · shares: These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and the Reporting Person at a purchase price of $3.13 per share. Read SEC document
June 14, 2023 Filed Jun 15, 2023 20:00 UTC	Damora Therapeutics, Inc. GLTO · Entity 4602	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $2.12	$0.00	Disclosure SEC source: 0001209191-23-037286 · doc4.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2023, the date of the Issuer's 2023 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document
June 05, 2023 Filed Jun 5, 2023 23:15 UTC	Zura Bio Ltd ZURA · Entity 5413	PurchaseClass A Ordinary Shares	117,647	$4.25	$499,999.75	Disclosure SEC source: 0001104659-23-068206 · tm2310288-1_4seq1.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 617,640 Read SEC document
June 01, 2023 Filed Jun 3, 2023 00:45 UTC	Zura Bio Ltd ZURA · Entity 5413	GrantEmployee Share Option (Right to Buy) · Derivative	1,130,000	$0.00 Strike: $6.25	$0.00	Disclosure SEC source: 0001104659-23-067722 · tm2317618-1_4seq1.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,130,000 Underlying: Class A Ordinary Shares · 1,130,000 shares Expires 2033-06-01 F1 · derivative.exercise_date: The Reporting Person was granted an option to purchase 1,130,000 Class A Ordinary Shares of the Issuer (the "Option") on June 1, 2023 (the "Grant Date"). The Option is vested and nonforfeitable as of the Grant Date. 25% of the Option shall become exercisable on June 1, 2024 and a further 2.083% of it shall become exercisable at the end of each month thereafter. Read SEC document
June 14, 2022 Filed Jun 15, 2022 20:00 UTC	Damora Therapeutics, Inc. GLTO · Entity 4602	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $1.98	$0.00	Disclosure SEC source: 0001209191-22-036936 · doc4.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-13 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document
March 11, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Disposition to issuerEmployee Performance Restricted Stock Unit · Derivative	42,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · derivative · entry 11 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,000 shares Expires not disclosed F6 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes. F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes. F6 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an "Issuer PRSU") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes. Read SEC document
March 11, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	168,000	Not disclosed Strike: $80.08	Not disclosed	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · derivative · entry 10 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 168,000 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document
March 11, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	270,000	Not disclosed Strike: $44.60	Not disclosed	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · derivative · entry 9 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 270,000 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document
March 11, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	285,000	Not disclosed Strike: $40.94	Not disclosed	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · derivative · entry 8 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 285,000 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document
March 11, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	310,000	Not disclosed Strike: $35.60	Not disclosed	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · derivative · entry 7 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 310,000 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document
March 11, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	56,861	Not disclosed Strike: $14.60	Not disclosed	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · derivative · entry 6 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,861 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document
March 11, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	138,139	Not disclosed Strike: $15.50	Not disclosed	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · derivative · entry 5 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 138,139 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document
March 11, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	OtherCommon Stock	85,847	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · nonDerivative · entry 4 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · kind: Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a "2022 Issuer RSU") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement). F4 · price: Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a "2022 Issuer RSU") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement). Read SEC document
March 11, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	OtherCommon Stock	28,800	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · nonDerivative · entry 3 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,847 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. Read SEC document
March 11, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	OtherCommon Stock	250	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · nonDerivative · entry 2 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,647 F2 · kind: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. F2 · price: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Read SEC document
March 08, 2022 Filed Mar 11, 2022 16:11 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GiftCommon Stock	10,500	$98.51	$1,034,355.00	Disclosure SEC source: 0001628280-22-005889 · wf-form4_164703301512029.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,897 F1 · kind: The reporting person gifted the shares to a 501(c)(3) public charity. Read SEC document
January 03, 2022 Filed Jan 5, 2022 17:01 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantCommon Stock	85,847	$0.00	$0.00	Disclosure SEC source: 0001628280-22-000341 · wf-form4_164142005362510.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,397 F1 · shares: The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on February 15, 2023, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of May, August, November, and February. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document
August 16, 2021 Filed Aug 17, 2021 08:30 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	PurchaseCommon Stock	1,000	$48.19	$48,190.00	Disclosure SEC source: 0001628280-21-017167 · wf-form4_162920341025660.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,550 Read SEC document
August 12, 2021 Filed Aug 13, 2021 08:10 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	PurchaseCommon Stock	1,000	$50.41	$50,410.00	Disclosure SEC source: 0001628280-21-016916 · wf-form4_162885659907660.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,550 Read SEC document
August 10, 2021 Filed Aug 11, 2021 08:04 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	PurchaseCommon Stock	1,000	$52.92	$52,915.00	Disclosure SEC source: 0001628280-21-016504 · wf-form4_162868348096069.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,550 Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:32 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantEmployee Performance Restricted Stock Unit · Derivative	42,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017582 · doc4.xml · derivative · entry 3 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2024-02-29 F3 · derivative.exercise_price: Each Employee Performance Restricted Stock Unit ("PRSU") represents a contingent right to receive shares of Arena's common stock, which shares shall vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from March 1, 2021, through February 29, 2024 (the "Performance Period") and satisfaction of a continuing service requirement. The reporting person was granted a "target" number of PRSUs equal to 50% of the number reported in Column 5. This Form 4 reports the "maximum" number of PRSUs, which equals 200% of "target" PRSUs, in order to reflect the maximum number of common shares issuable to the reporting person pursuant to the PRSUs. F4 · shares: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs. F4 · derivative.exercise_date: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs. F4 · derivative.underlying_shares: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs. F4 · balance_after: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs. Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:32 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantEmployee Stock Option (right to buy) · Derivative	168,000	$0.00 Strike: $80.08	$0.00	Disclosure SEC source: 0001209191-21-017582 · doc4.xml · derivative · entry 2 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,000 Underlying: Common Stock · 168,000 shares Expires 2028-03-01 F2 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on March 1, 2022, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:32 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantCommon Stock	28,800	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017582 · doc4.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,550 F1 · shares: The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on May 15, 2022, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of August, November, February, and May. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document
January 28, 2021 Filed Feb 2, 2021 02:45 UTC	Pulmatrix, Inc. PULM · Entity 8249	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $1.47	$0.00	Disclosure SEC source: 0001493152-21-002327 · ownership.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document
January 19, 2021 Filed Jan 20, 2021 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	50,000	$0.00 Strike: $15.50	$0.00	Disclosure SEC source: 0001209191-21-004584 · doc4.xml · derivative · entry 7 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,139 Underlying: Common Stock · 50,000 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. F4 · derivative.exercise_date: The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document
January 19, 2021 Filed Jan 20, 2021 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	SaleCommon Stock	50,000	$80.14	$4,006,760.00	Disclosure SEC source: 0001209191-21-004584 · doc4.xml · nonDerivative · entry 5 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,750 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.91, inclusive. Read SEC document
January 19, 2021 Filed Jan 20, 2021 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Exercise / conversionCommon Stock	50,000	$15.50	$775,000.00	Disclosure SEC source: 0001209191-21-004584 · doc4.xml · nonDerivative · entry 4 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. Read SEC document
January 15, 2021 Filed Jan 20, 2021 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	50,000	$0.00 Strike: $15.50	$0.00	Disclosure SEC source: 0001209191-21-004584 · doc4.xml · derivative · entry 6 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,139 Underlying: Common Stock · 50,000 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. F4 · derivative.exercise_date: The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document
January 15, 2021 Filed Jan 20, 2021 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	SaleCommon Stock	2,900	$81.06	$235,059.50	Disclosure SEC source: 0001209191-21-004584 · doc4.xml · nonDerivative · entry 3 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,750 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. Read SEC document
January 15, 2021 Filed Jan 20, 2021 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	SaleCommon Stock	47,100	$80.19	$3,776,916.03	Disclosure SEC source: 0001209191-21-004584 · doc4.xml · nonDerivative · entry 2 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,650 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.92, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. Read SEC document
January 15, 2021 Filed Jan 20, 2021 21:05 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	Exercise / conversionCommon Stock	50,000	$15.50	$775,000.00	Disclosure SEC source: 0001209191-21-004584 · doc4.xml · nonDerivative · entry 1 Munshi Amit · CIK 0001612551 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.